<DOC>
	<DOCNO>NCT01779570</DOCNO>
	<brief_summary>Influenza low respiratory tract infection ( LRTI ) major cause morbidity mortality worldwide . While viral replication suppress antiviral treatment , excessive inflammatory response , increasingly recognize contribute severe influenza complication , remain unopposed . Macrolides use widely treat community-acquired pneumonia , show exert anti-inflammatory effect respiratory disease , provide clinical benefit . In randomized , open-label , multicenter study , aim investigate anti-inflammatory effect macrolide treatment influenza LRTI . Its impact cytokine response , viral clearance , symptom disease resolution study . Such result may lead development new therapeutic approach severe influenza infection , provide good insight disease pathogenesis .</brief_summary>
	<brief_title>Anti-inflammatory Effects Macrolide Treatment Influenza Lower Respiratory Tract Infections</brief_title>
	<detailed_description>Objectives : ( 1 ) We aim investigate anti-inflammatory effect macrolide treatment patient influenza LRTI impact viral clearance . ( 2 ) To investigate impact macrolide treatment influenza symptom disease resolution . Design : A randomized , open-label , multicenter study . Settings : Acute medical facility 3 general public hospital Hong Kong . Subjects , Sampling Intervention : Adult ( &gt; /=18 year ) patient hospitalize virologically confirm influenza LRTI fulfill inclusion/exclusion criterion randomize receive ( 1 ) azithromycin 500 mg p.o . 5 day ( addition antiviral , part usual care ) , ( 2 ) azithromycin ( ie , antiviral alone , part usual care ) inform consent . Serial blood sample collect cytokine/inflammatory response assay . Serial nasopharyngeal swab collect assess viral clearance . Symptoms , clinical progress , radiography adverse event monitor .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1. establish influenza A B infection virologic test 2. age &gt; /=18 year 3. present within 4 day illness onset 4. clinical evidence LRTI require hospital care 5. require antiviral ( oseltamivir ) treatment 6. able provide write , informed consent . 1. patient immunosuppressant 2. pregnant lactate woman 3. know hepatic failure , endstage renal failure , cardiac arrhythmia ( e.g . prolong correct QT interval &gt; 450 msec ) 4. know contraindication azithromycin ( e.g . allergic reaction ) 5. lack consent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Macrolide</keyword>
	<keyword>Anti-inflammatory</keyword>
</DOC>